AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
LOPINAVIR AND RITONAVIR
7 registrations across 3 African markets— 5 active
Markets with LOPINAVIR AND RITONAVIR
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Lopinavir 100 mg and Ritonavir 25 mg Tablets Film-Coated Tablet | 🇰🇪Kenya | Aurobindo Pharma Limited | active | Aug 2026 |
| ALLTERA_50 40/10MG GRANULES GRANULES | 🇲🇼Malawi | — | expired | Mar 2025 |
| LOPINAVIR&_ROTONAVIR 200/50MG TABLET TABLET | 🇲🇼Malawi | — | expired | Mar 2025 |
| Lopinavir USP and Ritonavir USP Tablet, Film-coated | 🇹🇿Tanzania | LAURUS LABS LIMITED | active | — |
| Lopinavir USP & Ritonavir USP Tablet, coated | 🇹🇿Tanzania | Aurobindo Pharma Limited | active | — |
| Lopinavir and Ritonavir Tablet Film Coated Tablet | 🇹🇿Tanzania | Mylan Laboratories Limited | active | — |
| ALLTERA 50 Granules for Oral solution | 🇹🇿Tanzania | Mylan Laboratories Limited | active | — |
LOPINAVIR AND RITONAVIR in Africa — Regulatory Overview
LOPINAVIR AND RITONAVIR is registered across 3 African markets with 7 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tanzania, Malawi, Kenya. AfricaRegulatory refreshes this data daily from official government sources.
Of the 7 registrations, 5 (71%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.